The insulin-like growth factor system as a target in breast cancer.
Evidence from several experimental systems has shown that the insulin-like growth factors (IGFs) can stimulate breast cancer proliferation. Since IGF action is mediated by interaction with specific cell surface receptors, interruption of these signalling pathways could result in inhibition of cellular growth. In all extracellular fluids, the IGFs are associated with high affinity binding proteins, the IGFBPs can bind the IGFs and prevent receptor activation, and thus might have a role in a targeted approach to breast cancer therapy. Here we present our studies using IGFBP-1 to inhibit growth of the breast cancer cell line MCF-7.
Yee
D
D
Division of Medical Oncology, University of Texas Health Science Center at San Antonio 78284-7884.
D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D002352:Carrier Proteins / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1; D017451:Receptors, Somatomedin / Q000037:antagonists & inhibitors / Q000502:physiology; D013002:Somatomedins / Q000037:antagonists & inhibitors* / Q000502:physiology*; D014407:Tumor Cells, Cultured
D002352:Carrier Proteins; D018970:Insulin-Like Growth Factor Binding Protein 1; D017451:Receptors, Somatomedin; D013002:Somatomedins